Enanta Pharmaceuticals (ENTA) Other Non Operating Income (2012 - 2022)

Enanta Pharmaceuticals has reported Other Non Operating Income for 11 years, with the latest figure at $393000.0 in Q2 2022.

• For the quarter ending Q2 2022, Other Non Operating Income fell 10.48% year-over-year to $393000.0; the trailing twelve-month figure through Jun 2022 stood at -$782000.0 (up 78.64% YoY), and the FY2021 full-year result was -$27000.0, down 118.12% from the prior year.
• Other Non Operating Income for Q2 2022 stood at $393000.0, up from $255000.0 in the prior quarter.
• The five-year high for Other Non Operating Income was $2.4 million in Q2 2019, with the low at -$5.3 million in Q3 2020.
• Historically, Other Non Operating Income has averaged $222800.0 across 5 years, with a median of $393000.0 in 2022.
• Annual changes were most pronounced in 2018 — Other Non Operating Income plunged 115.15% — and 2019, when it surged 24050.0%.
• Enanta Pharmaceuticals' Other Non Operating Income stood at -$100000.0 in 2018, then surged by 2176.0% to $2.1 million in 2019, then tumbled by 67.39% to $677000.0 in 2020, then slumped by 61.89% to $258000.0 in 2021, then soared by 52.33% to $393000.0 in 2022.
• The last three Other Non Operating Income figures came in at $393000.0 (Q2 2022), $255000.0 (Q1 2022), and $258000.0 (Q4 2021), per Business Quant data.